Legal Opinion
In re Zostavax (Zoster Vaccine Live) Prods. Liab. Litig.
United States Judicial Panel on Multidistrict Litigation
Decided August 2, 2018No. MDL No. 2848PublishedCited by 2 opinions
1Opinion of the Court
SARAH S. VANCE, Chair
Before the Panel:* Defendants Merck & Co., Inc., and Merck Sharpe & Dohme Corp. (together, Merck) move under 28 U.S.C. § 1407 to centralize this litigation in the Eastern District of Pennsylvania or, alternatively, the Middle District of Florida or the Eastern District of New York. McKesson Corporation, a co-defendant in 30 actions, supports the motion. This litigation currently consists of 57 actions pending in nine districts, as listed on Schedule A. Since the filing of the motion, the Panel has been notified of 41 related federal actions.1
Plaintiffs in 15 actions on…
2Cases cited3 opinions
- In re Cook Medical, Inc., IVC Filters Marketing, Sales Practices & Products Liability LitigationUnited States Judicial Panel on Multidistrict Litigation · 2014
- In re Watson Fentanyl Patch Products Liability LitigationUnited States Judicial Panel on Multidistrict Litigation · 2012
- In re Fluoroquinolone Products Liability LitigationUnited States Judicial Panel on Multidistrict Litigation · 2015
3Cited by2 opinions
- Walker v. Merck & Co., Inc.District Court, W.D. North Carolina · 2022
- Walker, Sahara v. Merck & Co., Inc.District Court, W.D. Wisconsin · 2022